JPMorgan Downgrades Biogen (BIIB) to Neutral
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $202.63 +0.32%
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 7
Rating Summary:
29 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 7
Join SI Premium – FREE
JPMorgan analyst Cory Kasimov downgraded Biogen (NASDAQ: BIIB) from Overweight to Neutral with a price target of $244.00 (from $436.00).
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $320.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
- Morgan Stanley Downgrades Carrefour SA (CA:FP) (CRRFY) to Equalweight
- Biogen (BIIB) PT Lowered to $340 at Goldman Sachs
Create E-mail Alert Related Categories
DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
